（原标题：现场直击！第十一批国采开标） 21世纪经济报道记者 韩利明 10月27日，第十一批国家组织药品集中带量采购在上海市青浦区正式开标。本次集采共纳入55个品种， 涉及治疗领域主要包括抗感染、抗肿瘤、抗过敏哮喘、糖尿病用药、心血管用药、神经系统药物等。 根据现场公示的时间安排，上午7:00开始进行申报材料预检和企业签到；上午7：30-10：30集中受理申 报材料；10：30起公开申报信息，拟中选结果预计于今日晚些时候公布。10月28日将确认供应地区。 图：第十一批国采申报信息公开大会公告栏 开标前，现场已呈现忙碌景象。尚未到7：00，不少企业代表已在门口排队等待；也有企业代表围在一 起寒暄、讨论此次国采相关话题；附近多位工作人员在维持交通秩序。7：30一到，企业代表依次递交 资料、录入信息。 图：企业排队入场递交材料 2018年以来，国家层面已经开展了10批药品集采，覆盖了435种药品；地方也相继开展了省级和省际联 盟集采，形成了协同补充的工作格局。实践证明，集采是治理价格虚高的有效途径，推动了行业秩序逐 步规范，降低了群众用药负担，促进群众用药质量和可及性的整体提升。 根据央视新闻，本次国采规则全面优化 ...

Core Viewpoint - The article discusses the 11th batch of national organized drug procurement, highlighting its focus on transparency, quality assurance, and competitive pricing mechanisms in the pharmaceutical industry [3][10][13]. Group 1: Procurement Details - The 11th batch of drug procurement includes 55 varieties, covering treatment areas such as anti-infection, anti-tumor, asthma, diabetes, cardiovascular, and neurological drugs [3]. - The procurement process involved a two-round revival mechanism, allowing more companies to qualify, which is expected to extend the bidding time compared to previous batches [10]. - Since 2018, the national level has conducted 10 batches of drug procurement, covering 435 drugs and nearly 800 companies, involving over 2,000 representative products [10]. Group 2: Principles and Optimizations - The procurement adheres to principles of stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion [10][11]. - The reporting method for medical institutions has been optimized, allowing them to report either by generic name or specific brand, with 77% of the 46,000 institutions reporting by brand [10]. - Quality standards have been raised, requiring that production lines have no GMP violations in the past two years [10]. Group 3: Transparency and Competition - A significant highlight of this procurement is its emphasis on transparency, with the procurement office publicly explaining the selection rules and conducting online sessions for medical institutions [13]. - On average, 14 companies have applied for each variety, indicating that most companies are expected to qualify, although competition may be fierce for some varieties with a high number of bidders [13][15]. - The National Medical Insurance Administration issued a warning in August for companies to conduct cost-benefit analyses and maintain rational pricing in light of high competition [15].